EUVIMEDEUVIMED entdecken
Crossref

Development and Characterization of Solid Lipid Nanoparticles of Glecaprevir and Pibrentasvir for Enhanced Bioavailability in HCV Therapy

Prashant Bhoir, Manju Makhija, M K Gupta

International Journal of Drug Delivery Technology · 12.06.2026 · 16 (53s)

DOI: 10.25258/ijddt.16.53s.77 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 12.06.2026. Verfasst von Prashant Bhoir und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glecaprevir and Pibrentasvir are potent direct-acting antivirals (DAAs) approved by the USFDA for the treatment of hepatitis C virus (HCV) infections. However, their clinical utility is limited by poor aqueous solubility and suboptimal bioavailability. This study aimed to develop solid lipid nanoparticles (SLNs) for co-encapsulation of these drugs to enhance solubility, stability, and sustained release. SLNs were prepared using the microemulsion technique with stearic acid, glyceryl monostearate, and various surfactants. Formulations were optimized and characterized for particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE), drug loading, morphology, in vitro release, and stability. Optimized SLNs (F3) exhibited a mean particle size of 148.6 ± 5.2 nm, PDI of 0.21 ± 0.03, zeta potential of -28.4 ± 1.8 mV, and EE of 92.4% (Glecaprevir) and 89.7% (Pibrentasvir). SEM/TEM confirmed spherical morphology. In vitro release showed sustained biphasic release over 48 hours (85- 90% cumulative release). Formulations remained stable under ICH conditions for 90 days. SLNs significantly improved the physicochemical properties and release profile of Glecaprevir/Pibrentasvir, offering a promising nanocarrier system for enhanced HCV therapy.

Zitieren

APA

Bhoir, P., Makhija, M., & Gupta, M. K. (2026). Development and Characterization of Solid Lipid Nanoparticles of Glecaprevir and Pibrentasvir for Enhanced Bioavailability in HCV Therapy. International Journal of Drug Delivery Technology, 16(53s). https://doi.org/10.25258/ijddt.16.53s.77

Vancouver

Bhoir P, Makhija M, Gupta MK. Development and Characterization of Solid Lipid Nanoparticles of Glecaprevir and Pibrentasvir for Enhanced Bioavailability in HCV Therapy. International Journal of Drug Delivery Technology. 2026;16(53s). doi:10.25258/ijddt.16.53s.77

BibTeX
@article{Bhoir2026,
  author = {Bhoir, Prashant and Makhija, Manju and Gupta, M K},
  title = {Development and Characterization of Solid Lipid Nanoparticles of Glecaprevir and Pibrentasvir for Enhanced Bioavailability in HCV Therapy},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {53s},
  doi = {10.25258/ijddt.16.53s.77}
}
Kostenlos starten →